Genetic Loci for Retinal Arteriolar Microcirculation

Text S1

Text S1 contains the following information:

1. Sample selection and retinal vascular caliber measurements for each study cohort.

    a. Discovery cohorts

        i. Age, Gene/Environment Susceptibility – Reykjavik Study (AGES)

        ii. Atherosclerosis Risk in Communities Study (ARIC)

        iii. Cardiovascular Heart Study (CHS)

        iv. Rotterdam Study (RS)

        v. Blue Mountain Eye Study (BMES)

    b. Replication cohorts

        i. Australian Twin Study

        ii. Multi-Ethnic Study of Atherosclerosis (MESA)

2. Genotyping quality control filters and imputation of discovery cohorts

3. Meta-analysis

4. Analyses with Macrovascular diseases

5. References

1. **Sample selection and retinal vascular caliber measurements for each study cohort.**

a. Discovery cohorts

i. *Age Gene/Environment Susceptibility – Reykjavik Study (AGES)*

The original Reykjavik Study cohort consisted of a random sample of 30,795 men and women born from 1907 to 1935 and residing in Reykjavik in 1967 [1]. The AGES study re-examined 5,764 survivors from the original study. Among these, 3,219 participants were genotyped on the Illumina 370CNV BeadChip array. Sample exclusion criteria included sample failure, genotype mismatch with reference panel and gender discordance. Finally, 2,949 participants had both genome wide data and retinal vessel measurements.

Retinal images of each eye, centered on the macula and optic disc, were captured digitally using a 6.3 megapixel Canon R6 nonmydriatic camera with a Canon D-60 camera after maximal pharmacologic pupil dilation. Images with suboptimal quality, judged by a trained photographer, were retaken immediately. Throughout the study, the Ocular Epidemiology Reading Center (Madison, Wisconsin) provided routine feedback for the assessment of retinal images. Using a computer-assisted program and a standard protocol, measurements of retinal vessel caliber were made for all arterioles and venules in the area between 0.5 and 1.0 disc diameters from the optic disc margin [2]. Individual vessels measurements were combined by the Parr-Hubbard-Knudston formulas and summarized as the central retinal arteriole and venular equivalents (CRAE, CRVE) [3]. The inter-grader and intra-grader intra-class correlation coefficients ranged from 0.85 to 0.95 for CRAE and were consistently at 0.99 for CRVE.

In addition, the study was approved by the Icelandic National Bioethics Committee, VSN: 00-063 with written informed consent from all participants [4].

ii. *Atherosclerosis Risk in Communities Study (ARIC)*

The ARIC study is a prospective population-based study to investigate the etiology of atherosclerosis in four different US communities including non-Hispanic whites and African

Americans [5]. Detailed study design can be found on the ARIC study website (http://www.cscc.unc.edu/aric/). At baseline examination in 1987 to 1989, participants were between the age of 45 and 64. Blood was drawn at baseline for DNA extraction. Participants were genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 at the Broad Institute. For this study, only the non-Hispanic whites are included.

Retinal photos were taken at examination 3. Briefly, a 45° nonstereoscopic color retinal photograph was taken of one eye of each participant using a fundus camera that does not require pharmacologic dilation of the pupil (Canon CR-45UAF; Canon USA, Inc., Lake Success, New York). At the central reading center, a technician digitized the color slides at 3175 dots/inch resolution using a 35-mm film scanner (Nikon LS 3510 AF, Tokyo, Japan). The measurement module was custom programmed in Khoros (public domain image processing software from the University of New Mexico - Albuquerque) and the retinal measurements were summarized in micrometer (μm) using the Parr-Hubbard-Knudtson formulas [2,3]. Among three graders, the intra-grader and inter-grader intra-class correlation coefficients were 0.69 and 0.74 for CRAE and 0.89 and 0.77 for CRVE [2].

iii.   *Cardiovascular Health Study (CHS)*

The CHS is a population-based cohort study of risk factors for coronary heart disease and stroke in 5,201 persons, including 4,925 Europeans recruited in 1989 – 1990 [6]. An additional 687 African-Americans were enrolled into the study subsequently. At baseline, DNA was extracted from blood samples of participants who gave consent to genetic testing. The participants were genotyped on the Illumina 370CNV Duo BeadChip at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai. There were 1,263 participants, who were free of clinical cardiovascular disease at baseline and had both genotype data and retinal arteriole vessel measurements available for this study. Only those of European ancestry were included for this study.

Similar to the ARIC study, a 45° retinal photograph centered between the optic disc and the macula was obtained of one randomly selected eye using a non-mydriatic fundus camera after 5 minutes of dark adaptation (Canon CR-45UAF; Canon USA, Inc., Lake Success, New York). Photographs were digitized with a high-resolution scanner and evaluated according to a standardized protocol at the Fundus Photograph Reading Center in Madison, Wisconsin. The retinal measurements were summarized as CRAE and CRVE (in μm) using the Parr-Hubbard-Knudtson formulas [2,3]. The intra-grader and inter-grader intra-class correlation coefficients ranged from 0.67 to 0.91.

iv.   *Rotterdam Study (RS)*

The Rotterdam Study is a population-based cohort study conducted in a district of Rotterdam to examine the determinants of neurogeriatric, cardiovascular, bone, and eye diseases and health in the elderly [7]. Baseline measurements were obtained from 1990 to 1993 and consisted of an interview at home and two visits to the research center for physical examination, with written informed consent. In addition, DNA was extracted from all participants who consented to genotyping at baseline. Genotyping was performed in high-quality extracted DNA using the Illumina Infinum II HumanHap550chip v3.0 beadchip. Finally, a total of 4,820 participants had data on genotyping and retinal vessel measurements for the current analyses.

A full eye examination was implemented at baseline including taking fundus color transparencies of the optic disc (20^0 field, Topcon Optical Company, Tokyo, Japan) after pharmacological mydriasis. The transparencies from both eyes were digitized with a high-resolution scanner (Nikon LS-4000, Nikon Corporation, Japan), and the digitized image of one eye with the best quality was analyzed with the Retinal Vessel Measurement System (Retinal Analysis, Optimate, WI; Department of Ophthalmology & Visual Science, University of Wisconsin-Madison). For each participant one summary value was calculated for the arteriolar diameters (CRAE in μm) and one for the venular caliber (CRVE) [2,3]. Pearson's correlation

coefficients for inter-grader agreement were 0.67 – 0.80 for CRAE and 0.91 – 0.94 for CRVE. The corresponding figures were 0.69 – 0.88 and 0.90 – 0.95 for intra-grader agreement.

v.   *Blue Mountain Eye Study (BMES)*

The Blue Mountains Eye Study (BMES) is a population-based cohort of a predominantly white population in west of Sydney, Australia. At baseline (1992 – 1994), 3,654 permanent residents aged 49 years or older participated (participation rate of 82.4%) [8]. During 1997 – 1999 (BMES IIA), 2,335 participants (75.1% of survivors) returned for examinations during after 5 years. During 1999 – 2000, 1,174 (85.2%) new participants took part in an Extension Study of the BMES (BMES IIB). BMES cross-section II thus includes BMES IIA (66.5%) and BMES IIB (33.5%) participants (n = 3,509). From the BMES cross section II who had blood samples collected, DNA was extracted for 3,189 (90.1 %) participants.

Stereoscopic retinal photographs (30º) were taken for the macula, optic disc and other retinal fields of both eyes at each visit, using a Zeiss FF3 fundus camera (Carl Zeiss, Oberkochen, Germany) after pupil dilation. The retinal arteriolar and venular calibre was measured from the optic disc-centered photographs taken at baseline examinations, using a validated computer-assisted method [9]. A digitized grid was placed over the image and all vessels passing completely through a zone between 0.5 to 1 disc diameters away from the disc margin were measured, using the Retinal Analysis software (termed Howard program, Optimate, WI; Department of Ophthalmology & Visual Science, University of Wisconsin-Madison). For each vessel and branch, five equidistant measures were taken in μm. Estimates of CRAE and CRVE obtained from the Parr-Hubbard formulas were further converted into estimates equivalent to measures that were based on six largest arterioles and venules respectively of each eye, following the Parr-Hubbard-Knudtson formulas that was used by a newer computer-assisted program (IVAN program) [2,3]. Quadratic weighted kappa values were 0.85 for CRAE and 0.90 for

CRVE for inter-grader reliability respectively, and between 0.80-0.93 and 0.80-0.92 for intra-grader reliability of graders 1 and 2, respectively.

Participants of the BMES cross section II who had DNA available were genotyped (N = 2,761) using the Illumina Human 670-Quadv1 custom genotyping array at the Wellcome Trust Centre for Human Genetics, Sanger Institute, Cambridge as part of the Wellcome Trust Case Control Consortium 2 (WTCCC2). A smaller subset (N = 1,356) was also independently genotyped using the Illumina 610-Quad genotyping array at the Hunter Medical Research Institute, Newcastle, Australia, facilitating a detailed assessment of genotyping quality and reproducibility. Principal components (up to four dimensions) were used as covariates in the association analysis.

Imputation was performed using the Hapmap release 24 CEU panel (NCBI Build 36.1) as the imputation backbone, using only single nucleotide polymorphism (SNP) passing quality control (minor allele frequency MAF > 0.01, genotyping call rate > 0.95, Hardy-Weinberg Equilibrium (HWE) P-value > 1 x 10^{-6}) in both the WTCCC2 and Newcastle datasets. Genotype imputation was performed for autosomal SNPs using Markov Chain Haplotyping (MaCH) package v1.0.16 (http://www.sph.umich.edu/csg/abecasis/MACH/). Imputed genotypes were excluded if their ratio of observed to expected variance of imputed allele dosages (R^2) < 0.3 OR minor allele frequency < 0.01 OR Hardy-Weinberg P-value < 1 x 10^{-6}.

b. Replication cohorts

i. *Australian Twins Study*

The Australian Twin Eye Study consisted of participants examined as part of the Twins Eye Study in Tasmania (TEST) or the Brisbane Adolescent Twins Study (BATS) [10]. Participants were genotyped on the Illumina Human Hap610W Quad array, with part of the samples genotyped along with the UK Twins Cohort and the rest with DeCODE genetics. Complete phenotype and genetic data were available for 1,709 individuals.

Optic disc photographs were taken with a Nidek 3-Dx simultaneous stereoscopic 15° fundus camera (Nidek, Gamagori, Japan) in all subjects after instillation of tropicamide 1%. Images were developed on colored 35 mm slides (Ektachrome, Eastman Kodak, Rochester, New York) and further digitized (Nikon CoolScan IV ED slide scanner, Nikon Corp., Tokyo, Japan). Retinal vascular caliber was measured using the Parr-Hubbard-Knudtson formulas with computer-assisted software (IVAN, University of Wisconsin) and summarized as CRAE and CRVE [11]. Intra-grader and inter-grader intra-class correlation coefficients were very high for both CRAE (0.95, 0.93) and CRVE (0.99, 0.98).

For genotyping filters, the exclusion criteria for SNPs were MAF ≤ 1%, HWE P-value < 10^{-6}, SNP call rate ≤ 95% and Illumina Beadstudio Gencall Score < 0.7. Imputation was done against the backbone of Hapmap II release 22 CEU using MaCH2 (http://www.sph.umich.edu/csg/abecasis/MACH/) [12]. To account for the relatedness of the individuals, the association analysis was performed using the score test on Merlin (–fastAssoc option) (http://www.sph.umich.edu/csg/abecasis/merlin/) [13].

ii.   Multi-Ethnic Study of Atherosclerosis (MESA)

The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. MESA researchers study a diverse, population-based sample of 6,814 asymptomatic men and women aged 45 – 84 recruited from six field centers across the United States in 2000 and 2001. Among the recruited participants, 38% were white, 28% African-American, 22% Hispanic and 12% Asian, predominantly of Chinese descent [14]. Genome wide association scan (GWAS) and retinal data were available for 2,170 European subjects. Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0.

Fundus photography was offered to all participants at the second examination. Retinal images were acquired using a standardized protocol and a 45-degree nonmydriatic camera (Canon, Lake Success, New York) [15]. Retinal arteriolar caliber was, measured by the Ocular Epidemiology Reading Center (Madison Wisconsin) and employed the same standardized protocol and software used for the AGES study. The Parr-Hubbard-Knudtson formulas were used to compute summary measures for CRAE and CRVE in micrometer (µm).

IMPUTE version 2.1.0 [16] was used to perform imputation for the MESA European participants (chromosomes 1-22) using HapMap Phase I and II - CEU as the reference panel (release #24 - NCBI Build 36 (dbSNP b126)). SNPs with MAF less than 0.01 or HWE *P*-value < 0.0001 were removed from the analysis. Association tests were performed by SNPTEST v2 [17].

2. Genotyping quality control filters and imputation of discovery cohorts

Sample specific quality control filters used in the discovery cohorts included sample failure, sample call rate, sample heterozygosity, excessive Mendelian errors in the samples, outliers identified by IBS clustering analysis and gender discordance [18]. SNP quality control filters included call rates, minor allele frequency, Hardy-Weinberg equilibrium and differential missingness by outcome or genotype [18].

The discovery cohorts were screened for latent population substructure using suitable programs (i.e, EIGENSTRAT in ARIC and AGES [19,20], an identity-by-descent IBD matrix in Rotterdam, principal component analysis in CHS and multi-dimensional scaling in BMES [21]) and found no evidence of occult population admixture. BMES in addition, corrected for the first four principal components in their regression analysis, to retain more samples.

For imputation, high quality SNP data was used as seed for imputation in each study. These criteria included call rates (> 97% in AGES, > 95% in ARIC and CHS, ≥ 95% in BMES, > 98% in RS), MAF filtering of greater than 0.01 in each study, Hardy-Weinberg filtering (HWE *P*-

value $> 1 \times 10^{-5}$ in CHS and P-value $> 1 \times 10^{-6}$ in AGES, ARIC, RS and BMES), and differential

missingness filter of P-value $> 1 \times 10^{-9}$ in each study. Genotype imputation for discovery cohorts

was performed using the MACH package (http://www.sph.umich.edu/csg/abecasis/MACH) [12]

(version 1.0.15 for ARIC and RS; v1.0.16 for AGES and BMES) and BIMBAM10 v0.99 [22] for

CHS. All the cohorts imputed with the reference panel of Hapmap II CEU release 22 build 36,

except CHS which imputed against the reference panel of Hapmap II CEU release 21A build 35.

The ratio of the empirically observed dosage variance to the expected binomial dosage variance

was estimated as a reliability measure of imputation for each SNP.

We checked bivariate plots of $-\log 10$ observed P-value against $-\log 10$ empirical P-value

(P-P) plots to ensure that the p-value distribution in each of the discovery cohorts conformed to a

null distribution except at the extreme tail. The genomic inflation factor (λ_{gc}) measuring the over-

dispersion of test-statistics from association tests were 1.040 for AGES, 1.036 for ARIC, 1.041

for CHS, 1.039 for RS and 1.004 for BMES.

3. Meta-analysis

Each cohort had approximately 2.5 million SNPs either genotyped or imputed for meta-

analysis (2,408,992 for AGES, 2,475,681 for ARIC2, 250,210 for CHS and 2,447,961 for RS and

2,411,691 for BMES). 2,137,729 SNPs were common across all the discovery cohorts and only

SNPs that were present in all 5 cohorts were selected for follow-up.

The inverse variance fixed effects meta-analysis method was used for the meta-analysis,

with genomic control applied to each cohort prior to meta-analysis. Larger weights were given to

studies with bigger samples sizes, directly genotyped SNPs and SNPs with high quality

imputation. The meta-analysis was implemented using METAL

(http://www.sph.umich.edu/csg/abecasis/Metal/index.html). The genomic inflation factor after

meta-analysis was 1.022812.

4. Analyses with Macrovasular Diseases

i.   Wellcome Trust Case Control Consortium (WTCCC)

The Wellcome Trust Case Control Consortium (WTCCC) was established to look into the design and analyses of GWA studies and published their landmark paper on the case control analyses of seven common diseases and a set of common controls [17]. The seven diseases included bipolar disorder (BD), coronary artery disease (CAD), Crohn's disease (CD), hypertension (HT), rheumatoid arthritis (RA), type 1 diabetes (T1D), and type 2 diabetes (T2D). CAD cases were defined as having a validated history of either myocardial infarction or coronary revascularization (coronary artery bypass surgery or percutaneous coronary angioplasty) before their 66th birthday and verified from hospital records or the primary care physician. The control samples were from two sources, the 1958 Birth Cohort and a new UK Blood Service which was established specifically for this study and is a UK national repository of anonymized DNA samples from 3,622 consenting blood donors. Imputation was performed using the Markov Chain Haplotyping (MaCH) package (http://www.sph.umich.edu/csg/abecasis/MACH) [12] with Hapmap CEU as the reference panel. Logistic regression was performed using, the estimated dosage of the effective allele from MaCH and the ProbABEL program (http://mga.bionet.nsc.ru/~yurii/ABEL/) [23] with no adjustment for covariates.

ii.   The Heart and Vascular Health Study (HVH)

The Heart and Vascular Health Study (HVH) is a population-based case-control study within Group Health (GH) in western Washington State. Myocardial Infarction (MI) cases were GH enrollees, 30 to 79 years of age, who had an incident MI between 1995 and 2006, and alive at the time of study recruitment. Stroke cases were also GH enrollees, 30 to 79 years of age, who had an incident stroke between 1995 and 2008, and alive at the time of study recruitment. Hospital discharge diagnosis codes were used to identify cases and further validated by medical record review as previously described [24]. Control subjects were made up of a stratified random sample

of GH enrollees frequency matched to MI cases on age (within decade), sex, hypertension status, and calendar year of identification. If participants were recent enrollees at GH, had a history of prior MI or stroke, or if the incident MI or stroke was a complication of a procedure or surgery, they were excluded from the study. All participants provided written informed consent.

iii.   Global Blood Pressure Genetics (Global BPgen) Consortium

The Global BPgen consortium comprises of 17 individual GWAS studies [25]: the Baltimore Longitudinal Study of Aging (BLSA), British 1958 Birth Cohort (B58C-T1DGC and B58C-WTCCC), Cohorte Lausannoise (CoLaus), Diabetes Genetics Initiative (DGI), European Prospective Investigation of Cancer-Norfolk-Genome Wide Association Study (EPIC-Norfolk-GWAS), Fenland Study, Finland-United States Investigation of NIDDM Genetics (FUSION) study, Invecchiare in Chianti (InCHIANTI), Kooperative Gesundheitsforschung in der Region Augsburg (KORA), the Myocardial Infarction Genetics Consortium (MIGen), Northern Finland Birth Cohort of 1966 (NFBC1966), SardiNIA, Study of Health in Pomerania (SHIP), the Precocious Coronary Artery Disease (PROCARDIS), Supplementation en Vitamines et Mine´raux Antioxydants (SU.VI.MAX) and TwinsUK. Individuals >70 years of age, ascertained on case status for type 1 or 2 diabetes (DGI, FUSION), coronary artery disease (MIgen, PROCARDIS) or hypertension (BRIGHT), were excluded for analysis. Hypertension was defined as either (i) systolic blood pressure ≥ 140 mm Hg or (ii) diastolic blood pressure ≥90 mm Hg or (iii) self-reported hypertension medication. Normotensive controls were defined as individuals not taking any antihypertensives and having a systolic blood pressure ≤ 120 mm Hg and a diastolic blood pressure ≤ 85 mm Hg. Analysis of hypertension was done using logistic regression to adjust for age, age^2, sex and body mass index (BMI) for 34,433 individuals.

iv.   Genetics of Diabetes and Audit Research in Tayside Scotland (GoDARTS)

GoDARTS is a population based case control study in Tayside, Scotland to study the epidemiology and genetics of Type 2 Diabetes [26]. Participants were recruited between 2004 to 2009 and linked to routinely collected medical records available for the Tayside region. Participants with coronary artery disease (CAD) were identified from medical records. These included hospital admissions and deaths due to myocardial infarction and unstable angina, and participants who underwent coronary revascularization. Stroke was defined as hospital admissions and deaths associated with ischemic stroke.

Quality controlled genotyping data for the SNPs of interest were available for 3,328 diabetics genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0.

A multivariate Cox regression analysis was performed on incident CAD and incident ischemic stroke using the survival package in R (http://CRAN.R-project.org/package=survival) [27]. Incident events were defined as events that occurred after participants were recruited into the study. They were followed up until their first stroke or CAD event or death from other causes or until the end of the censoring period. Baseline measures were recorded at the time of recruitment. An additive mode was used where the effect allele was coded as the allele that reduced arteriolar caliber with age, gender, body mass index, history of smoking, previous coronary artery disease/stroke events at baseline included as covariates in the analysis.

A multivariable logistic regression analysis was also performed in prevalent cases of CAD in GoDARTS, corrected for age, gender, BMI, history of smoking and use of hypertension medication.

5. References

1. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, et al. (2007) Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol 165: 1076-1087.

2. Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, et al. (1999) Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 106: 2269-2280.

3. Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, et al. (2003) Revised formulas for summarizing retinal vessel diameters. Curr Eye Res 27: 143-149.

4. Qiu C, Cotch MF, Sigurdsson S, Garcia M, Klein R, et al. (2008) Retinal and cerebral microvascular signs and diabetes: the age, gene/environment susceptibility-Reykjavik study. Diabetes 57: 1645-1650.

5. (1989) The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 129: 687-702.

6. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, et al. (1991) The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1: 263-276.

7. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, et al. (2009) The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 24: 553-572.

8. Mitchell P, Smith W, Attebo K, Wang JJ (1995) Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 102: 1450-1460.

9. Leung H, Wang JJ, Rochtchina E, Tan AG, Wong TY, et al. (2003) Relationships between age, blood pressure, and retinal vessel diameters in an older population. Invest Ophthalmol Vis Sci 44: 2900-2904.

10. Mackey DA, Mackinnon JR, Brown SA, Kearns LS, Ruddle JB, et al. (2009) Twins eye study in Tasmania (TEST): rationale and methodology to recruit and examine twins. Twin Res Hum Genet 12: 441-454.

11. Sun C, Zhu G, Wong TY, Hewitt AW, Ruddle JB, et al. (2009) Quantitative genetic analysis of the retinal vascular caliber: the Australian Twins Eye Study. Hypertension 54: 788-795.

12. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34: 816-834.

13. Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin--rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30: 97-101.

14. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, et al. (2002) Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 156: 871-881.

15. Klein R, Klein BE, Knudtson MD, Wong TY, Cotch MF, et al. (2006) Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 113: 373-380.

16. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39: 906-913.

17. (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.

18. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, et al. (2009) Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of

prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2: 73-80.

19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909.

20. Patterson N, Price AL, Reich D (2006) Population structure and eigenanalysis. PLoS Genet 2: e190.

21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.

22. Servin B, Stephens M (2007) Imputation-based analysis of association studies: candidate regions and quantitative traits. PLoS Genet 3: e114.

23. Aulchenko YS, Struchalin MV, van Duijn CM (2010) ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11: 134.

24. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, et al. (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274: 620-625.

25. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet.

26. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, et al. (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315: 524-528.

27. Therneau T (2011) Survival: Survival analysis, including penalised likelihood. 2.36-9 ed.

SNP (chr: position)	Ref/Effective allele (+)	Cohort	Eff allele freq	Beta (SE)	P-value	Genes of interest
rs2194025 (5: 87833992)	C/G	AGES	0.95	-1.30 (0.79)	9.74×10^{-2}	*TMEM16B*
		ARIC	0.90	-1.25 (0.36)	4.33×10^{-4}	*MEF2C*
		CHS	0.91	-3.14 (0.99)	2.00×10^{-3}	
		RS	0.90	-1.46 (0.48)	2.29×10^{-3}	
		BMES	0.90	-2.45 (0.74)	9.72×10^{-4}	
		Cohort	Eff allele freq	Beta (SE)	P-value	Genes of interest
rs3744061 (17: 72244998)	A/G	AGES	0.46	-0.96 (0.35)	6.23×10^{-3}	*SFRS2*
		ARIC	0.44	-1.03 (0.21)	1.53×10^{-6}	*MFSD11*
		CHS	0.43	-1.16 (0.60)	6.00×10^{-2}	*JMJD6*
		RS	0.42	-0.27 (0.30)	3.72×10^{-1}	*MXRA7*
		BMES	0.45	-0.52 (0.45)	2.43×10^{-1}	
		Cohort	Eff allele freq	Beta (SE)	P-value	Genes of interest
rs2281827 (13: 27899721)	T/C	AGES	0.78	-1.27 (0.44)	4.09×10^{-3}	*FLT1*
		ARIC	0.77	-0.40 (0.26)	1.18×10^{-1}	
		CHS	0.73	-1.08 (0.70)	1.20×10^{-1}	
		RS	0.78	-1.61 (0.37)	1.47×10^{-5}	
		BMES	0.76	-0.96 (0.52)	6.46×10^{-2}	

SE: standard error, AGES: Age Gene/Environment Susceptibility – Reykjavik Study, ARIC: Atherosclerosis Risk in Communities Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study, BMES: Blue Mountains Eye Study.

The allele that decreases retinal arteriolar caliber is presented as the effective allele.

Diabetes mellitus, in AGES, ARIC, CHS and BMES, is defined by self-reported, fasting blood glucose $\geq$ 126 mg/dL (7.0 mmol/L), and/or medication use. In RS, diabetes mellitus was defined as defined as a non-fasting glucose level $\geq$ 11.0 mmol/l and/or antidiabetic medication use.

SNP (chr: position)	Next best SNP (r^2) (G/I)	Ref/Effective allele (+)	Cohort	Eff allele freq	Beta (SE)	P-value	Genes of interest
rs2194025 (5: 87833992)	rs2194026 (r^2 = 1) (GIGGG)	G/T	Discovery cohorts combined	0.91	-1.56 (0.25)	2.35×10^{-10}	*TMEM16B*
			MESA Whites	0.91	-2.01 (0.76)	8.00×10^{-3}	*MEF2C*
			Australian Twins	0.91	-1.14 (0.83)	1.68×10^{-1}	
			Replication cohorts combined	0.91	-1.62 (0.56)	3.97×10^{-3}	
			Discovery + Replication cohorts combined	0.90	-1.56 (0.22)	3.43×10^{-12}	
			Cohort	Eff allele freq	Beta (SE)	P-value	Genes of interest
rs3744061 (17: 72244998)	rs9916811 (r^2 = 0.844) (GGGGG)	C/T	Discovery cohorts combined	0.48	-0.75 (0.14)	1.05×10^{-8}	*SFRS2*
			MESA Whites	0.48	-0.49 (0.51)	2.50×10^{-1}	*MFSD11*
			Australian Twins	0.50	1.70 (0.49)	4.84×10^{-4}	*JMJD6*
			Replication cohorts combined	0.49	0.44 (0.32)	1.62×10^{-1}	*MXRA7*
			Discovery + Replication cohorts combined	0.48	-0.55 (0.13)	1.77×10^{-5}	
			Cohort	Eff allele freq	Beta (SE)	P-value	Genes of interest
rs2281827 (13: 27899721)	rs722503 (r^2 = 0.529) (GIGGG)	T/C	Discovery cohorts combined	0.76	-0.84 (0.17)	9.38×10^{-7}	*FLT1*
			MESA Whites	0.74	-0.25 (0.51)	6.30×10^{-1}	
			Australian Twins	0.25	-0.57 (0.57)	3.08×10^{-1}	
			Replication cohorts combined	0.52	-0.40 (0.38)	2.94×10^{-1}	
			Discovery + Replication cohorts combined	0.72	-0.72 (0.16)	9.75×10^{-7}	

SE: standard error, OR: odds ratio, MESA: Multi-Ethnic Study of Atherosclerosis.

The allele that decreases retinal arteriolar caliber is presented as the effective allele (refer to Table 2).

r^2: linkage disequilibrium r^2 between the SNP reported in the main paper and the next best index SNP from SNAP (http://www.broadinstitute.org/mpg/snap/ldsearch.php) using Europeans from Hapmap II.

(G/I): Indicates if the SNP is directly genotyped (G) or imputed (I), given in the following order: AGES: Age Gene/Environment Susceptibility – Reykjavik Study, ARIC: Atherosclerosis Risk in Communities Study, CHS: Cardiovascular Health Study, RS: Rotterdam Study, BMES: Blue Mountains Eye Study.

Table S3 – Membership of Wellcome Trust Case Control Consortium 2

Management Committee
Peter Donnelly (Chair)[1,2], Ines Barroso (Deputy Chair)[3], Jenefer M Blackwell[4, 5], Elvira Bramon[6], Matthew A Brown[7], Juan P Casas[8], Aiden Corvin[9], Panos Deloukas[3], Audrey Duncanson[10], Janusz Jankowski[11], Hugh S Markus[12], Christopher G Mathew[13], Colin NA Palmer[14], Robert Plomin[15], Anna Rautanen[1], Stephen J Sawcer[16], Richard C Trembath[13], Ananth C Viswanathan[17], Nicholas W Wood[18]

Data and Analysis Group
Chris C A Spencer[1], Gavin Band[1], Céline Bellenguez[1], Colin Freeman[1], Garrett Hellenthal[1], Eleni Giannoulatou[1], Matti Pirinen[1], Richard Pearson[1], Amy Strange[1], Zhan Su[1], Damjan Vukcevic[1], Peter Donnelly[1,2]

DNA, Genotyping, Data QC and Informatics Group
Cordelia Langford[3], Sarah E Hunt[3], Sarah Edkins[3], Rhian Gwilliam[3], Hannah Blackburn[3], Suzannah J Bumpstead[3], Serge Dronov[3], Matthew Gillman[3], Emma Gray[3], Naomi Hammond[3], Alagurevathi Jayakumar[3], Owen T McCann[3], Jennifer Liddle[3], Simon C Potter[3], Radhi Ravindrarajah[3], Michelle Ricketts[3], Matthew Waller[3], Paul Weston[3], Sara Widaa[3], Pamela Whittaker[3], Ines Barroso[3], Panos Deloukas[3].

Publications Committee
Christopher G Mathew (Chair)[13], Jenefer M Blackwell[4,5], Matthew A Brown[7], Aiden Corvin[9], Mark I McCarthy[19], Chris C A Spencer[1]

[1] Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7LJ, UK;
[2] Dept Statistics, University of Oxford, Oxford OX1 3TG, UK;
[3] Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK;
[4] Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, 100 Roberts Road, Subiaco, Western Australia 6008;
[5] Cambridge Institute for Medical Research, University of Cambridge School of Clinical Medicine, Cambridge CB2 0XY, UK;
[6] Department of Psychosis Studies, NIHR Biomedical Research Centre for Mental Health at the Institute of Psychiatry, King's College London and The South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AF, UK;
[7] Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia;
[8] Dept Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT and Dept Epidemiology and Public Health, University College London WC1E 6BT, UK;
[9] Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine, Trinity College Dublin, Dublin 2, Eire;
[10] Molecular and Physiological Sciences, The Wellcome Trust, London NW1 2BE;
[11] Centre for Digestive Diseases, Queen Mary University of London, London E1 2AD, UK and Digestive Diseases Centre, Leicester Royal Infirmary, Leicester LE7 7HH, UK and Department of Clinical Pharmacology, Old Road Campus, University of Oxford, Oxford OX3 7DQ, UK;
[12] Clinical Neurosciences, St George's University of London, London SW17 0RE;
[13] King's College London Dept Medical and Molecular Genetics, School of Medicine, Guy's Hospital, London SE1 9RT, UK;
[14] Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK;
[15] King's College London Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK;
[16] University of Cambridge Dept Clinical Neurosciences, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK;
[17] NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK;
[18] Dept Molecular Neuroscience, Institute of Neurology, Queen Square, London WC1N 3BG, UK;
[19] Oxford Centre for Diabetes, Endocrinology and Metabolism (ICDEM), Churchill Hospital, Oxford OX3 7LJ, UK.

Table S4 – Membership of the Global Blood Pressure Genetics (Global BPgen) consortium

Christopher Newton-Cheh[1,2,3], Toby Johnson[4,5,6], Vesela Gateva[7], Martin D Tobin[8], Murielle Bochud[5], Lachlan Coin[9], Samer S Najjar[10], Jing Hua Zhao[11,12], Simon C Heath[13], Susana Eyheramendy[14,15], Konstantinos Papadakis[16], Benjamin F Voight[1,3], Laura J Scott[7], Feng Zhang[17], Martin Farrall[18,19], Toshiko Tanaka[20,21], Chris Wallace[22,23], John C Chambers[9], Kay-Tee Khaw[12,24], Peter Nilsson[25], Pim van der Harst[26], Silvia Polidoro[27], Diederick E Grobbee[28], N Charlotte Onland-Moret[28,29], Michiel L Bots[28], Louise V Wain[8], Katherine S Elliott[19], Alexander Teumer[30], Jian'an Luan[11], Gavin Lucas[31], Johanna Kuusisto[32], Paul R Burton[8], David Hadley[16], Wendy L McArdle[33], Wellcome Trust Case Control Consortium[34], Morris Brown[35], Anna Dominiczak[36], Stephen J Newhouse[22], Nilesh J Samani[37], John Webster[38], Eleftheria Zeggini[19,39], Jacques S Beckmann[4,40], Sven Bergmann[4,6], Noha Lim[41], Kijoung Song[41], Peter Vollenweider[42], Gerard Waeber[42], Dawn M Waterworth[41], Xin Yuan[41], Leif Groop[43,44], Marju Orho-Melander[25], Alessandra Allione[27], Alessandra Di Gregorio[27,45], Simonetta Guarrera[27], Salvatore Panico[46], Fulvio Ricceri[27], Valeria Romanazzi[27,45], Carlotta Sacerdote[47], Paolo Vineis[9,27], Ineˆs Barroso[12,39], Manjinder S Sandhu[11,12,24], Robert N Luben[12,24], Gabriel J. Crawford[3], Pekka Jousilahti[48], Markus Perola[48,49], Michael Boehnke[7], Lori L Bonnycastle[50], Francis S Collins[50], Anne U Jackson[7], Karen L Mohlke[51], Heather M Stringham[7], Timo T Valle[52], Cristen J Willer[7], Richard N Bergman[53], Mario A Morken[50], Angela Do¨ring[15], Christian Gieger[15], Thomas Illig[15], Thomas Meitinger[54,55], Elin Org[56], Arne Pfeufer[54], H Erich Wichmann[15,57], Sekar Kathiresan[1,2,3], Jaume Marrugat[31], Christopher J O'Donnell[58,59], Stephen M Schwartz[60,61], David S Siscovick[60,61], Isaac Subirana[31,62], Nelson B Freimer[63], Anna-Liisa Hartikainen[64], Mark I McCarthy[19,65,66], Paul F O'Reilly[9], Leena Peltonen[39,49], Anneli Pouta[64,67], Paul E de Jong[68], Harold Snieder[69], Wiek H van Gilst[26], Robert Clarke[70], Anuj Goel[18,19], Anders Hamsten[71], John F Peden[18,19], Udo Seedorf[72], Ann-Christine Syva¨nen[73], Giovanni Tognoni[74], Edward G Lakatta[10], Serena Sanna[75], Paul Scheet[76], David Schlessinger[77], Angelo Scuteri[78], Marcus Do¨rr[79], Florian Ernst[30], Stephan B Felix[79], Georg Homuth[30], Roberto Lorbeer[80], Thorsten Reffelmann[79], Rainer Rettig[81], Uwe Vo¨lker[30], Pilar Galan[82], Ivo G Gut[13], Serge Hercberg[82], G Mark Lathrop[13], Diana Zeleneka[13], Panos Deloukas[12,39], Nicole Soranzo[17,39],
Frances M Williams[17], Guangju Zhai[17], Veikko Salomaa[48], Markku Laakso[32], Roberto Elosua[31,62], Nita G Forouhi[11], Henry Vo¨lzke[80], Cuno S Uiterwaal[28], Yvonne T van der Schouw[28], Mattijs E Numans[28], Giuseppe Matullo[27,45], Gerjan Navis[68], Go¨ran Berglund[25], Sheila A Bingham[12,83], Jaspal S Kooner[84], John M Connell[36], Stefania Bandinelli[85], Luigi Ferrucci[21], Hugh Watkins[18,19], Tim D Spector[17], Jaakko Tuomilehto[52,86,87], David Altshuler[1,3,88,89], David P Strachan[16], Maris Laan[56], Pierre Meneton[90], Nicholas J Wareham[11,12], Manuela Uda[75], Marjo-Riitta Jarvelin[9,67,91], Vincent Mooser[41], Olle Melander[25], Ruth JF Loos[11,12], Paul Elliott[9], Goncalo R Abecasis[92], Mark Caulfield[22], Patricia B Munroe[22]

1. Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA
2. Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
3. Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, 02142, USA
4. Department of Medical Genetics, University of Lausanne, 1005 Lausanne, Switzerland
5. University Institute for Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, 1005 Lausanne, Switzerland
6. Swiss Institute of Bioinformatics, Switzerland
7. Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109, USA
8. Departments of Health Sciences & Genetics, Adrian Building, University of Leicester, University Road, Leicester LE1 7RH
9. Department of Epidemiology and Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK
10. Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, National Institutes of Health,
Baltimore, Maryland, USA 21224
11. MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
12. Cambridge - Genetics of Energy Metabolism (GEM) Consortium, Cambridge, UK

13. Centre National de Génotypage, 2 rue Gaston Crémieux, CP 5721, 91 057 Evry Cedex, France
14. Pontificia Universidad Catolica de Chile, Vicuña Mackenna 4860, Facultad de Matematicas, Casilla 306, Santiago 22, Chile, 7820436
15. Institute of Epidemiology, Helmholtz Zentrum München, German Research Centre for Environmental Health, 85764 Neuherberg, Germany
16. Division of Community Health Sciences, St George's, University of London, London SW17 0RE, UK
17. Department of Twin Research & Genetic Epidemiology, King's College London, London SE1 7EH
18. Department of Cardiovascular Medicine, University of Oxford
19. The Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK
20. Medstar Research Institute, 3001 S. Hanover Street, Baltimore, MD 21250, USA
21. Clinical Research Branch, National Institute on Aging, Baltimore, MD, 21250 USA
22. Clinical Pharmacology and The Genome Centre, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ
23. JDRF/WT Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research University of Cambridge, Wellcome Trust/MRC Building, Addenbrooke's Hospital Cambridge, CB2 0XY
24. Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge CB2 2SR, UK
25. Department of Clinical Sciences, Lund University, Malmo University Hospital, SE-20502 Malmo, Sweden26. Department of Cardiology University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
27. ISI Foundation (Institute for Scientific Interchange), Villa Gualino, Torino, 10133, Italy
28. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, STR 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands
29. Complex Genetics Section, Department of Medical Genetics - DBG, University Medical Center Utrecht, STR 2.2112, PO Box 85500, 3508 GA Utrecht, The Netherlands.
30. Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
31. Cardiovascular Epidemiology and Genetics, Institut Municipal d'Investigació Mèdica, Barcelona, Spain
32. Department of Medicine University of Kuopio 70210 Kuopio, Finland
33. ALSPAC Laboratory, Department of Social Medicine, University of Bristol, BS8 2BN, UK
34. A full list of authors is provided in the supplementary methods online.
35. Clinical Pharmacology Unit, University of Cambridge, Addenbrookes Hospital, Cambridge, UK CB2 2QQ
36. BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK G12 8TA
37. Department of Cardiovascular Science, University of Leicester, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK
38. Aberdeen Royal Infirmary, Aberdeen, UK
39. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK
40. Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 1011, Switzerland
41. Genetics Division, GlaxoSmithKline, King of Prussia, PA 19406, USA
42. Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) 1011 Lausanne, Switzerland
43. Department of Clinical Sciences, Diabetes and Endocrinology Research Unit, University Hospital, Malmö
44. Lund University, Malmö S-205 02, Sweden
45. Department of Genetics, Biology and Biochemistry, University of Torino, Torino, 10126, Italy
46. Department of Clinical and Experimental Medicine, Federico II University, Naples, 80100, Italy
47. Unit of Cancer Epidemiology, University of Turin and Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, 10126, Italy
48. National Institute for Welfare and Health P.O. Box 30, FI-00271 Helsinki, Finland
49. Institute for Molecular Medicine Finland FIMM, University of Helsinki and National Public Health Institute
50. Genome Technology Branch, National Human Genome Research Institute, Bethesda, MD 20892, USA
51. Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA

52. Diabetes Unit, Department of Epidemiology and Health Promotion, National Public Health Institute, 00300 Helsinki, Finland
53. Physiology and Biophysics USC School of Medicine 1333 San Pablo Street, MMR 626 Los Angeles, California 90033
54. Institute of Human Genetics, Helmholtz Zentrum München, German Research Centre for Environmental Health, 85764 Neuherberg, Germany
55. Institute of Human Genetics, Technische Universität München, 81675 Munich, Germany
56. Institute of Molecular and Cell Biology, University of Tartu, 51010 Tartu, Estonia
57. Ludwig Maximilians University, IBE, Chair of Epidemiology, Munich
58. Cardiovascular Research Center and Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
59. Framingham Heart Study and National, Heart, Lung, and Blood Institute, Framingham, Massachusetts 01702, USA
60. Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, 98101 USA
61. Department of Epidemiology, University of Washington, Seattle, Washington, 98195 USA
62. CIBER Epidemiología y Salud Pública, Barcelona, Spain
63. Center for Neurobehavioral Genetics, Gonda Center, Room 3506, 695 Charles E Young Drive South, Box 951761, UCLA, Los Angeles, CA 90095.
64. Department of Clinical Sciences/Obstetrics and Gynecology, P.O. Box 5000 Fin-90014, University of Oulu, Finland
65. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK
66. Oxford NIHR Biomedical Research Centre, Churchill Hospital, Old Road, Headington, Oxford, UK OX3 7LJ
67. Department of Child and Adolescent Health, National Public Health Institute (KTL), Aapistie 1, P.O. Box 310, FIN-90101 Oulu, Finland
68. Division of Nephrology, Department of Medicine University Medical Center Groningen, University of Groningen, Hanzeplein 1,
9700 RB Groningen, The Netherlands
69. Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands
70. Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK
71. Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital Solna, Building L8:03, S-17176 Stockholm, Sweden
72. Leibniz-Institut fü r Arterioskleroseforschung an der Universität Münster, Domagkstr. 3, D-48149, Münster, Germany
73. Molecular Medicine, Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala, Sweden
74. Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro (Chieti), Italy
75. Istituto di Neurogenetica e Neurofarmacologia, CNR, Monserrato, 09042 Cagliari, Italy
76. Department of Epidemiology, Univ. of Texas M. D. Anderson Cancer Center, Houston, TX 77030
77. Laboratory of Genetics, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA 21224
78. Unitá Operativa Geriatria, Istituto Nazionale Ricovero e Cura per Anziani (INRCA) IRCCS, Rome, Italy
79. Department of Internal Medicine B, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
80. Institute for Community Medicine, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
81. Institute of Physiology, Ernst-Moritz-Arndt-University Greifswald, 17487 Greifswald, Germany
82. U557 Institut National de la Santé et de la Recherche Médicale, U1125 Institut National de la Recherche Agronomique, Université Paris 13, 74 rue Marcel Cachin, 93017 Bobigny Cedex, France
83. MRC Dunn Human Nutrition Unit, Wellcome Trust/MRC Building, Cambridge CB2 0XY, U.K
84. National Heart and Lung Institute, Imperial College London SW7 2AZ

85. Geriatric Rehabilitation Unit, Azienda Sanitaria Firenze (ASF), 50125, Florence, Italy
86. Department of Public Health, University of Helsinki, 00014 Helsinki, Finland
87. South Ostrobothnia Central Hospital, 60220 Seinä joki, Finland
88. Department of Medicine and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
89. Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
90. U872 Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine Paris Descartes, 15 rue de l'Ecole de Médecine, 75270 Paris Cedex, France
91. Institute of Health Sciences and Biocenter Oulu, Aapistie 1, FIN-90101, University of Oulu, Finland
92. Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109 USA